A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.

Hartman ML, Clayton PE, Johnson ML, Celniker A, Perlman AJ, Alberti KG, Thorner MO

The Journal of clinical investigation1 Jun 1993Cited by 103 (Europe PMC)

PMID8514857PMCIDPMC443305DOI10.1172/jci116480PepBankPUB-08514857

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanNon-randomized trialPharmacokinetics
IGF-I infusion increased total IGF-I threefold in fasted normal men.
In plain wordsIGF-I infusion increased total IGF-I levels in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseTotal IGF-I
Study
n = 10
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Total IGF-I increase
3 fold
During rhIGF-I infusion, fasted normal men
Source sentences
Summary
As a result of rhIGF-I infusion, total and free IGF-I concentrations increased three- and fourfold, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485701
02HumanNon-randomized trialPharmacokinetics
IGF-I infusion increased free IGF-I fourfold in fasted normal men.
In plain wordsIGF-I infusion increased free IGF-I levels in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseFree IGF-I
Study
n = 10
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Free IGF-I increase
4 fold
During rhIGF-I infusion, fasted normal men
Source sentences
Summary
As a result of rhIGF-I infusion, total and free IGF-I concentrations increased three- and fourfold, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485702
03HumanNon-randomized trialEfficacy outcome
IGF-I infusion reduced mean GH concentrations in fasted normal men after 120 min.
In plain wordsIGF-I infusion reduced growth hormone levels in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseMean GH concentration
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Mean GH concentration
6.3 micrograms/liter
Before the fall
Mean GH concentration
0.59 micrograms/liter
After 120 min of rhIGF-I
Reported +/- term for mean GH concentration
1.6 micrograms/liter
Before the fall; uncertainty type not stated in the summary
Reported +/- term for mean GH concentration
0.07 micrograms/liter
After 120 min of rhIGF-I; uncertainty type not stated in the summary
Source sentences
Summary
Mean GH concentrations fell from 6.3 +/- 1.6 to 0.59 +/- 0.07 micrograms/liter after 120 min.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485703
04HumanNon-randomized trialEfficacy outcome
IGF-I suppressed GH secretion within 60 min in fasted normal men, while secretion remained elevated with saline.
In plain wordsIn fasted normal men, IGF-I suppressed growth hormone secretion while it remained elevated with saline.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGH secretion rate
Study
n = 10
Comparator
Saline infusion
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Half-time of GH secretion rate decrease
16.6 min
During rhIGF-I infusion
Time to suppression of GH secretion rate
≤ 60 min
During rhIGF-I infusion
Source sentences
Summary
GH secretion rates, calculated by a deconvolution algorithm, decreased with a t 1/2 of 16.6 min and remained suppressed thereafter.
4 context sentences(design, population, supporting numbers)
Summary · context
Suppression of GH secretion rates occurred within 60 min when total and free IGF-I concentrations were 1.6-fold and 2-fold above baseline levels, respectively, and while glucose infusion rates were < 1 mumol.kg-1.min-1.
Summary · context
During saline infusion, GH secretion rates remained elevated.
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485704
05HumanNon-randomized trialEfficacy outcome
IGF-I reduced GH mass secreted per pulse by 84% in fasted normal men.
In plain wordsIGF-I reduced the amount of growth hormone released per pulse in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGH mass per pulse
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
GH mass secreted per pulse decrease
84%
During rhIGF-I infusion
P value for GH mass secreted per pulse
< 0.01 dimensionless
rhIGF-I versus saline control in fasted normal men
Source sentences
Summary
Infusion of rhIGF-I decreased the mass of GH secreted per pulse by 84% (P < 0.01) and the number of detectable GH secretory pulses by 32% (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485705
06HumanNon-randomized trialEfficacy outcome
IGF-I reduced detectable GH pulses by 32% in fasted normal men.
In plain wordsIGF-I reduced the number of growth hormone pulses in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGH pulse number
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Number of detectable GH secretory pulses decrease
32%
During rhIGF-I infusion
P value for number of detectable GH secretory pulses
< 0.05 dimensionless
rhIGF-I versus saline control in fasted normal men
Source sentences
Summary
Infusion of rhIGF-I decreased the mass of GH secreted per pulse by 84% (P < 0.01) and the number of detectable GH secretory pulses by 32% (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485706
07HumanNon-randomized trialEfficacy outcome
IGF-I reduced insulin to nearly undetectable levels after 60 min in fasted normal men.
In plain wordsIGF-I reduced insulin to nearly undetectable levels in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseInsulin
Study
n = 10
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Source sentences
Summary
Plasma insulin and glucagon decreased to nearly undetectable levels after 60 min of rhIGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485707
08HumanNon-randomized trialEfficacy outcome
IGF-I reduced glucagon to nearly undetectable levels after 60 min in fasted normal men.
In plain wordsIGF-I reduced glucagon to nearly undetectable levels in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGlucagon
Study
n = 10
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Source sentences
Summary
Plasma insulin and glucagon decreased to nearly undetectable levels after 60 min of rhIGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485708
09HumanNon-randomized trialEfficacy outcome
IGF-I did not affect free fatty acids during the first 3 h in fasted normal men.
In plain wordsIGF-I initially did not change free fatty acids in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeFree fatty acids during first hours
Study
n = 10
Outcome group
Lipids · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Source sentences
Summary
Serum free fatty acids, beta-hydroxybutyrate, and acetoacetate were unaffected during the first 3 h of rhIGF-I but decreased thereafter to 52, 32, and 50% of levels observed during saline.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485709
10HumanNon-randomized trialEfficacy outcome
After the first 3 h, IGF-I reduced free fatty acids to 52% of saline levels in fasted normal men.
In plain wordsIn fasted normal men, IGF-I later reduced free fatty acids below levels with saline.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseFree fatty acids after initial hours
Study
n = 10
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Free fatty acids
52 % of levels observed during saline
after the first 3 h of rhIGF-I infusion, versus saline
Source sentences
Summary
Serum free fatty acids, beta-hydroxybutyrate, and acetoacetate were unaffected during the first 3 h of rhIGF-I but decreased thereafter to 52, 32, and 50% of levels observed during saline.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485710
11HumanNon-randomized trialEfficacy outcome
IGF-I did not affect beta-hydroxybutyrate during the first 3 h in fasted normal men.
In plain wordsIGF-I initially did not change beta-hydroxybutyrate in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBeta-hydroxybutyrate during first hours
Study
n = 10
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Source sentences
Summary
Serum free fatty acids, beta-hydroxybutyrate, and acetoacetate were unaffected during the first 3 h of rhIGF-I but decreased thereafter to 52, 32, and 50% of levels observed during saline.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485711
12HumanNon-randomized trialEfficacy outcome
After the first 3 h, IGF-I reduced beta-hydroxybutyrate to 32% of saline levels in fasted normal men.
In plain wordsIn fasted normal men, IGF-I later reduced beta-hydroxybutyrate below levels with saline.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseBeta-hydroxybutyrate after initial hours
Study
n = 10
Comparator
Saline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Beta-hydroxybutyrate
32 % of levels observed during saline
after the first 3 h of rhIGF-I infusion, versus saline
Source sentences
Summary
Serum free fatty acids, beta-hydroxybutyrate, and acetoacetate were unaffected during the first 3 h of rhIGF-I but decreased thereafter to 52, 32, and 50% of levels observed during saline.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485712
13HumanNon-randomized trialEfficacy outcome
IGF-I did not affect acetoacetate during the first 3 h in fasted normal men.
In plain wordsIGF-I initially did not change acetoacetate in fasted normal men.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeAcetoacetate during first hours
Study
n = 10
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Source sentences
Summary
Serum free fatty acids, beta-hydroxybutyrate, and acetoacetate were unaffected during the first 3 h of rhIGF-I but decreased thereafter to 52, 32, and 50% of levels observed during saline.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485713
14HumanNon-randomized trialEfficacy outcome
After the first 3 h, IGF-I reduced acetoacetate to 50% of saline levels in fasted normal men.
In plain wordsIn fasted normal men, IGF-I later reduced acetoacetate below levels with saline.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseAcetoacetate after initial hours
Study
n = 10
Comparator
Saline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
10 micrograms.kg-1.h-1 · infusion · 6 hAs given in this study (human).
Measurements
Acetoacetate
50 % of levels observed during saline
after the first 3 h of rhIGF-I infusion, versus saline
Source sentences
Summary
Serum free fatty acids, beta-hydroxybutyrate, and acetoacetate were unaffected during the first 3 h of rhIGF-I but decreased thereafter to 52, 32, and 50% of levels observed during saline.
2 context sentences(design, population, supporting numbers)
Summary · context
To determine if insulin-like growth factor I (IGF-I) inhibits pulsatile growth hormone (GH) secretion in man, recombinant human IGF-I (rhIGF-I) was infused for 6 h at 10 micrograms.kg-1.h-1 during a euglycemic clamp in 10 normal men who were fasted for 32 h to enhance GH secretion.
Summary · context
Saline alone was infused during an otherwise identical second admission as a control.
Report a problemFND-0851485714

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.

Summary

Results from this study14

Version history

Subjects

Publication types

MeSH terms